Surgical orchiectomy vs. medical castration in treatment of metastatic prostate cancer

A new study in JAMA Oncology has suggested that surgical orchiectomy may have lower risk for complications and side effects than medical castration with LHRH agonists (also known as GnRH agonists) like leuprolide acetate (Lupron) and others in treatment of men newly diagnosed with metastatic prostate cancer. This is a complex issue! … READ MORE …

Cardiovascular side effects and the early use of ADT — another large data set analysis

A newly published paper in BJU International has expanded our understanding of the cardiovascular risks associated with the use of androgen deprivation therapy (ADT) — most particularly in older men treated with ADT as their first-line form of therapy. … READ MORE …

Colorectal cancer among prostate cancer patients treated with ADT

As if it wasn’t long enough already, the list of adverse events “associated with” the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is growing. … READ MORE …

The news report: Tuesday, April 7, 2009

Today’s news report covers articles on:

  • Prevention of prostate cancer and other prostate disorders
  • Pelvic lymph node dissection
  • Sexual activity at 15 years after radiation therapy
  • Non-hormonal, non-surgical orchiectomy
  • Another possible prostate cancer drug … READ MORE …

Thursday’s prostate cancer news: November 13, 2008

Today’s reports include items on:

  • Perceptions of pain and discomfort in men undergoing DRE
  • 10-year survival data of men with pT3 disease treated initially with a radical prostatectomy
  • Orchiectomy, medical castration, and acceptable social costs
  • Hemi-body radiation to treat pain in men with multiple bone metastases … READ MORE …